More than three-quarters of evaluable patients had a tumor-associated antigen-specific immune response. CVGBM, an investigational cancer vaccine, induced immune responses in more than three-quarters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback